Presbyopia eye drops
Anti-crosslinking drug may restore natural accommodation
![Presbyopia eye drops](/media/2zebqq0t/ophthalmologistoffice_vector.png?width=1640&height=500&v=1da86bd014d3930)
![Howard Larkin](/media/afbhkiu1/howard.png?width=350&height=350&v=1d876d4d72d1570)
Howard Larkin
Published: Tuesday, July 11, 2017
![](http://www.eurotimes.org/wp-content/uploads/2017/07/Richard-L-Lindstrom-HS-240x300.jpg)
EV06 targets disulfide bonds that form among proteins in the crystalline lens in response to oxidative challenge and UV light that both stiffen and cloud the lensEventually, EV06 or a similar preparation might also help slow or even reverse nuclear cataract formation, which is thought to result from the same chemical process that causes presbyopia, added Dr Lindstrom, who is founder of Minnesota Eye Consultants, Bloomington, Minnesota, USA, and a board member and equity owner of Encore Vision. EV06 targets disulfide bonds that form among proteins in the crystalline lens in response to oxidative challenge and UV light that both stiffen and cloud the lens. The choline preparation helps the compound penetrate the cornea. Inside the eye, it reduces to lipoic acid and dihydrolipoic acid, which in turn dissolve the disulfide bonds. “We’re basically un-crosslinking the natural lens,” Dr Lindstrom said. In the clinical trial, involving 75 patients, EV06 worked faster than expected, and the effect increased progressively throughout the trial, Dr Lindstrom said. Mean logMAR distance corrected near visual acuity in the treatment group improved from 0.397 at baseline to 0.206 at day 91, compared with 0.408 at baseline to 0.313 at day 91 in the control group. At day 91, 84% reached 20/40 or better from a baseline of 30% in the treatment group, compared with 48% from 28% among controls. Overall, 84% of treated patient gained at least one line of near vision, 53% two or more lines and 22% three lines, and 12% four lines at 90 days, with no loss of corrected distance vision. While a few patients reported minor irritation taking EV06 twice daily, comfort scores were similar in the treatment and placebo groups. No significant adverse events were observed and no patients dropped out of the trial. A post-treatment study found the treated group continued to show better near vision than controls out to 301 days, though the effect declined slightly over time, Dr Lindstrom added. Richard L Lindstrom: rllindstrom@ mneye.com
Tags: presbyopia
Latest Articles
Finding a Keratoconus Consensus
Evolving new consensus should help guide diagnosis and management.
Ray of a New Dawn in Corneal Infection Research
Will UVC light the way as a potential treatment for microbial keratitis?
Towards a More Inclusive Ophthalmology
The only way to face challenges to inclusivity and equity is to work together without barriers.
Refractive Femtosecond Laser
There are many different femtosecond laser surgical platforms to choose from, and it can be hard to keep them all straight. We have prepared a table allowing you to compare these at a glance, along with some comments from some of our members who use these lasers regularly.
Survey Informing New Leadership and Business Programmes in 2024
A year-round programme will complement Leadership and Business Innovation Day at the 2024 Annual Congress.
Overcoming Obstacles to Presbyopia-Correcting IOLs
New technology can smooth the path to premium IOL acceptance.
The Power of Four
Finding uses for corneal lenticules, once considered a waste product.
Alternative to Penetrating Keratoplasty
Cornea findings and comorbidities considered in surgical decisions for endothelial dysfunction.
Flexing Four-Flanged Scleral Fixation
Study results reveal 80% of patients end up with good refractive outcomes.